Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

NCT06013618 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: Naxitamab monotherapy
DRUG: GM-CSF
DRUG: Irinotecan
DRUG: Temozolomide
DRUG: Naxitamab in combination therapy
DRUG: GM-CSF with combination regimen
DRUG: Sintilimab

Sponsor

Sun Yat-Sen University Cancer Center

Collaborators

[object Object]